CollaGenex Periostat NDA filed for oral doxycycline to treat periodontitis.
COLLAGENEX PERIOSTAT ORAL DOXYCYCLINE DENTAL NDA FILED for treatment of periodontitis on Aug. 30, the Newtown, Penn. dental therapies R&D firm announced Sept. 4. The NDA includes data on three Phase III trials of 436 patients; the 12-month dosing trials found that Periostat demonstrated both clinically and statistically significant improvements in tooth attachment levels, gum pocket depth and bleeding upon probing. The daily dosage is 20 mg doxycycline.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth